There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on KemPharm (KMPH) and Abeona Therapeutics (ABEO) with bullish sentiments.
KemPharm (KMPH)
In a report released today, Oren Livnat from H.C. Wainwright initiated coverage with a Buy rating on KemPharm and a price target of $3. The company’s shares closed yesterday at $1.80, close to its 52-week low of $1.15.
Livnat wrote:
“We are Initiating coverage of Buy rating and $3 price target. KemPharm is a specialty pharmaceutical company that develops prodrugs of existing approved molecules. KemPharm’s lead assets are KP415, a prodrug of methylphenidate (MPH) designed to have best-in-class onset and duration and lower abusability, and Apadaz, a prodrug of hydrocodone designed to be a less abusable Vicodin. Apadaz is approved, partnered, and soon to launch, while KP415 should be partnered imminently. Since going public in 2015 during the abuse-deterrent opioid rush, the company has had setbacks, first in 2016 when the FDA determined that Apadaz hadn’t proven abuse deterrence vs Vicodin, then last summer when KP415 pivotal topline data showed a disappointing efficacy onset and duration profile.”
According to TipRanks.com, Livnat is a 4-star analyst with an average return of 10.9% and a 52.8% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Verrica Pharmaceuticals Inc, Taiwan Liposome Company Ltd, and Collegium Pharmaceutical.
Currently, the analyst consensus on KemPharm is a Moderate Buy with an average price target of $3.
See today’s analyst top recommended stocks >>
Abeona Therapeutics (ABEO)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Abeona Therapeutics, with a price target of $23. The company’s shares closed yesterday at $5.01, close to its 52-week low of $4.98.
Selvaraju observed:
“Valuation methodology, risks and uncertainties. We ascribe a total risk-adjusted net present value (rNPV) of $1.46B to Abeona’s technology platforms, which yields a price per share of $25.00 based on about 64M shares outstanding as of end-1Q 2020.”
According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 1.3% and a 30.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Abeona Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $23.60, which is a 371.1% upside from current levels. In a report issued on June 7, Mizuho Securities also reiterated a Buy rating on the stock with a $17 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
